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Abstract
Surfactant Protein SP-D, a member of the collectin family, is a pattern recognition protein, secreted by mucosal epithelial
cells and has an important role in innate immunity against various pathogens. In this study, we confirm that native human
SP-D and a recombinant fragment of human SP-D (rhSP-D) bind to gp120 of HIV-1 and significantly inhibit viral replication in
vitro in a calcium and dose-dependent manner. We show, for the first time, that SP-D and rhSP-D act as potent inhibitors of
HIV-1 entry in to target cells and block the interaction between CD4 and gp120 in a dose-dependent manner. The rhSP-D-
mediated inhibition of viral replication was examined using three clinical isolates of HIV-1 and three target cells: Jurkat T
cells, U937 monocytic cells and PBMCs. HIV-1 induced cytokine storm in the three target cells was significantly suppressed
by rhSP-D. Phosphorylation of key kinases p38, Erk1/2 and AKT, which contribute to HIV-1 induced immune activation, was
significantly reduced in vitro in the presence of rhSP-D. Notably, anti-HIV-1 activity of rhSP-D was retained in the presence of
biological fluids such as cervico-vaginal lavage and seminal plasma. Our study illustrates the multi-faceted role of human SP-
D against HIV-1 and potential of rhSP-D for immunotherapy to inhibit viral entry and immune activation in acute HIV
infection.
Citation: Pandit H, Gopal S, Sonawani A, Yadav AK, Qaseem AS, et al. (2014) Surfactant Protein D Inhibits HIV-1 Infection of Target Cells via Interference with
gp120-CD4 Interaction and Modulates Pro-Inflammatory Cytokine Production. PLoS ONE 9(7): e102395. doi:10.1371/journal.pone.0102395
Editor: Kevan L. Hartshorn, Boston University School of Medicine, United States of America
Received March 24, 2014; Accepted June 17, 2014; Published July 18, 2014
Copyright:  2014 Pandit et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: The work (Project no. 2011-16850) was supported by Medical Innovation Fund of Indian Council of Medical Research, New Delhi, India (www.icmr.nic.
in/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: taruna_m@hotmail.com
¤ Current address: Department of Molecular Biosciences, University of Texas, Austin, Austin, Texas, United States of America
Introduction
Acute HIV infection is marked by a pro-inflammatory
‘‘cytokine storm’’ that promotes viral replication and mediate
immunopathology [1]. This leads to a non-specific activation and
proliferation of naı¨ve CD4+ T cells providing the ideal micro-
environment for viral replication. Resident macrophages and
CD4+ T cells in the draining lymph nodes are one of the first
immune cells that come in contact with the virus. Upon viral
challenge, monocytes/macrophages induce high levels Th1
cytokines (IFN-c, IL-2 and IL-12), pro-inflammatory cytokines
(TNF-a, IL-1b, IL-6) and certain chemokines that favor the
formation of viral reservoirs with strongly increased viral
transcription [2]. Similarly, infected CD4+ T cells are known to
induce levels of IL-2, IL-6, and TNF-a and synergistically induce
HIV-1 replication [3]. These series of events lead to successful
viral entry and dissemination. Thus, a protective anti-viral
response would require a tight regulation of the excessive immune
activation. Recent anti-HIV-1 vaccine design and prevention
strategies are focused on regulating such initial, generalized
immune activation that can curb viral replication [4].
Surfactant Protein SP-D, a member of the collectin family, is a
pattern recognition innate immune molecule that brings about
clearance of various pathogens via agglutination, and enhanced
phagocytosis and killing. In the process, SP-D also modulates
pathogen mediated pro-inflammatory effects on macrophages and
T cells [5]. The primary structure of human SP-D is characterized
by an N-terminal, triple-helical collagen region, an a-helical
coiled-coil neck region, and a homotrimeric C-type lectin domain
or carbohydrate recognition domain (CRD), which resembles
Surfactant Protein SP-A (SP-A) and Mannose Binding Lectin
(MBL), other members of the collectin family [6]. The trimeric
CRD interacts with glycosylated moieties on the pathogen surface,
mediating agglutination and inhibiting infectivity. Through its
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CRD and collagen domains, SP-D interacts with immune cells via
various receptors such as calreticulin/CD91, SIRPa, and CD14
on the cell surface, and thus, regulates effector functions [7,8]. SP-
D down-regulates LPS-elicited inflammatory responses by macro-
phage and inhibits TNF-a production [9]. SP-D also exerts its
inhibitory effects on the proliferation of CD4+ T cells and IL-2
production [10,11]. In response to allergens, SP-D modulates T
cells response by up-regulating CTLA4; a negative regulator of T
cell activation [12]. Similar to SP-D, a recombinant fragment of
SP-D, composed of homotrimeric neck and CRD region, has been
shown to reduce inflammation in several pathophysiological
conditions [13].
SP-D binds to the HIV-1 surface protein gp120 and signifi-
cantly inhibits replication in U937 monocytes [14] and PM1 T
cells [15]. Moreover, SP-D is secreted by mucosal epithelial cells
and is present in the vaginal tract [16], and thus, likely to be
relevant for sexual transmission of HIV. There are reports that
appear to suggest regulation of SP-D levels in different stages of
HIV infection. Serum SP-D levels are increased in patients with
AIDS, but not in early HIV infection [17]. On initiation of anti-
retroviral therapy (ART) and subsequent suppression of HIV
replication, serum SP-D levels are reported to decrease signifi-
cantly [18]. These two clinical correlates suggest regulation of SP-
D expression during HIV pathogenesis.
Using three clinical isolates of HIV-1 that are different in
tropism, and three target cells, we show here that SP-D as well as
rhSP-D are potent inhibitors of HIV entry and block the
interaction between CD4 and gp120 in a dose-dependent manner.
The rhSP-D also suppresses significantly pro-inflammatory cyto-
kines induced by HIV-1 in Jurkat T cells, U937 monocytes and
activated PBMCs. Such cytokine suppression appears to be
associated with reduced signaling as evident from reduced
phosphorylation of AKT and MEK/ERK in presence of rhSP-
D. Thus, SP-D has a multi-faceted and hierarchical protective role
in host defense against HIV-1. We also report that the anti-HIV-1
properties of rhSP-D remain unaltered in the presence of cervico-
vaginal lavage and seminal plasma, raising the possibility that the
recombinant protein may have a prophylactic value.
Results
SP-D and rhSP-D recognize HIV-1 glycoproteins gp41,
gp120 and gp160
SP-D has previously been shown to bind gp120 [14,15]. We
carried out ligand blot analysis in order to assess what HIV-1
antigens were being recognized by SP-D and rhSP-D using a
commercially available HIV antigen coated strip. Both SP-D and
rhSP-D showed binding to envelope HIV-1 glycoproteins gp41,
gp120 and gp160 (Fig 1A). No binding was observed to any other
HIV-1 antigens. When soluble HIV-1 gp120 was immobilized and
probed with serial dilutions of SP-D or rhSP-D (0.4–2 mg/ml),
there was a dose- and calcium-dependent binding that was
inhibited by EDTA (Fig 1B). Since structural conformation of
surface expressed gp120 may impose restrictions on the flexibility
of this interaction, we evaluated the interaction of gp120
expressing HL2/3 cells with SP-D using a FITC labeled
polyclonal antibody raised against gp120. The mean fluorescence
intensity of the FITC labeled cells was reduced significantly in
presence of rhSP-D (Fig 1C) as well as SP-D (data not shown)
compared to untreated control.
In silico analysis of SP-D -gp120 interaction
In silico studies were carried out to identify potential binding
sites of SP-D in gp120. Since, experimental observations have
shown that SP-D binds gp120 through glycan mediated interac-
tions [14], we screened the docked solutions for complexes
wherein CRD of SP-D bound to gp120 via glycan mediated
interactions (Figure S1). The shortlisted docked poses were further
refined by FireDock and the best pose was selected for further
analysis (Table S1).
An analysis of the best docked complex revealed that SP-D
(CRD) interacts with glycans at Asn234 and Asn276 and various
residues in the known CD4 binding regions namely C2, C4 and
C5 domains of gp120 [19] (Fig. 2Ai, ii). Recently, it has been
reported that 8ANC195, which is an anti-gp120 glycan-dependent
antibody, requires intact N-linked glycosylation sites of gp120 at
Asn234 and Asn276 for sustaining its neutralizing activity. These
glycosylation sites are known to be conserved and are proximal to
CD4 binding site [20]. Interestingly, it was observed that SP-D
(CRD) interacts with the glycans of these residues in the docked
complex. The experimental and in silico observations appear to
suggest that SP-D could impact binding of CD4 to gp120 and
could therefore serve as a potent viral entry inhibitor.
SP-D and rhSP-D inhibit gp120-CD4 interaction and act
as cell entry inhibitor of HIV-1
We further carried out a competitive assay to assess whether SP-
D or rhSP-D inhibited binding of gp120 to CD4 expressing
lymphocytes, using FITC labeled polyclonal antibody to gp120.
Percentage gp120-bound lymphocytes (FITC positive cells) were
significantly reduced in the presence of rhSP-D (at 1 mg;
74.3260.5%, at 2 mg 48.3263.2%), compared to untreated
control (taken as 100%) (Fig 2B ii). At concentration of 10 mg,
percentage of FITC positive cells reduced to 28.7362.8%. A
similar dose dependent decrease was observed with SP-D (at 1 mg/
ml; 68.8162.7%, at 2 mg/ml 32.7461.7%).
A cell-based assay, where gp120 expressing HL2/3 cells were
fused with CD4 expressing TZM-bl cells, was performed to further
confirm SP-D or rhSP-D mediated inhibition of gp120-CD4
interaction. Such an assay system is helpful in determining entry
inhibitors of HIV-1. SP-D as well as rhSP-D showed dose-
dependent decrease in the numbers of b-gal positive cells or virus
infected cells (Fig 2C). At a concentration of 20 mg/ml, SP-D or
rhSP-D showed only 7.0362.03% and 5.961.76% blue stained
cells, respectively, when compared with control (taken as 100%).
Anti-HIV-1 activity of SP-D
To evaluate anti-HIV activity of SP-D, we used the TZM-bl cell
line which is highly sensitive to infection with a range of HIV-1
isolates. SP-D and rhSP-D showed a significant reduction in
infectivity down to 34.7263.11% and 37.665.76%, respectively,
as compared to control cells (taken as 100%) (Fig 3A). The
reduction in infectivity observed at the same concentration of
rhSP-D and SP-D was not significantly different and could be due
to a considerably higher molar concentration of rhSP-D
(1 mg,16.761023 mM) than SP-D (1 mg,1.961023 mM). Subse-
quent experiments were carried out using rhSP-D only.
Anti-HIV-1 activity of rhSP-D is independent of viral
tropism and is intact in the presence of CVL and SP
Various HIV-1 strains/isolates exhibit different level of tropism
that is in part determined by glycosylation level/pattern [21].
Since SP-D is a carbohydrate pattern recognition molecule, we
sought to examine the ability of rhSP-D to inhibit four different
HIV-1 isolates with distinct tropism. The strains included one
laboratory strain, HIV-LAI that utilizes X4, and three primary
isolates: R5 tropic 93IN905, X4 tropic 98IN017, and R5X4R3
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tropic 96USNG31. A significant dose-dependent rhSP-D-mediat-
ed inhibition of viral infection was observed with all the four viral
strains (Fig 3B). The IC50 values did not vary significantly with
differences in viral tropism or subtype (Table 1). Cell viability was
evaluated to confirm that reduction in viral replication was not due
to cell death (Fig S2A).
To examine efficacy of rhSP-D in post-coital conditions, we
studied anti-HIV activity of rhSP-D in the presence of biological
fluids such as CVL and SP, which differ in terms of pH, secretory
proteins and proteases. We observed that the anti-HIV-1 activity
of rhSP-D remained intact in the presence of CVL and SP
(Fig 3C). Since SP-D is present in vaginal mucosa and tract [16], it
was expected that SP-D may retain its functions in these
secretions.
rhSP-D inhibits HIV-1 infection in Jurkat and U937 cell
lines as well as activated PBMCs
CD4 T cells and monocyte/macrophages are the primary
targets of HIV infection and activated PBMCs are known to be
more susceptible to HIV infection. Thus, we assessed the anti-HIV
activity of rhSP-D in Jurkat T cells, U937 monocytic cell line and
activated PBMCs. As shown in Fig 4 (A–C), rhSP-D significantly
inhibited HIV-1 infection in all three target cells tested in a dose-
dependent manner over a period of 12 days. Furthermore, during
the assay period, cellular viability was not affected in the presence
of rhSP-D, as determined by MTT assay performed on day12 (Fig
S2B), suggesting that the reduced infectivity was not due to the
cellular death. We did not observe a significant difference in the
inhibitory activity of rhSP-D between different cell types and the
activity was persistent even with primary cells (PBMCs) as HIV-1
target.
rhSP-D significantly inhibits pro-inflammatory cytokine
production by HIV-1 challenged Jurkat T cells, U937
monocytes and activated PBMCs
Cytokine response of the HIV challenged immune cells was
determined with or without rhSP-D. There was a significant rise in
the levels of pro-inflammatory cytokines such as IL-1a, IL-1b, IL-
2, IL-6, IL-8, TNF-a, VEGF, IFN-c and MCP-1 in U937
monocytes, Jurkat T cells and PBMCs after 24h of HIV-1
challenge (Table S2, S3, S4). Levels of IL-2, IFN- and VEGF
were considerably reduced in the rhSP-D treated Jurkat, U937
and primary cells (PBMCs) in a dose-dependent manner. (Fig 5A,
B, C). Levels of IL-1a and TNF-a were also significantly lowered
in Jurkat cells (Fig 5A). Similarly, IL-6, a major pro-inflammatory
cytokine in HIV infection, and a chemokine MCP-1, were reduced
in U937 monocytes (Fig 5B). Additionally, PBMCs also showed a
decrease in IL-6, MCP-1 and IL-1b (Fig 5C). Other cytokines
(Table S1) that were up-regulated upon HIV-1 challenge were not
significantly altered by rhSP-D. This indicates that rhSP-D
successfully controls most of the pro-inflammatory cytokine
production induced by HIV-1. Viability of uninfected and infected
cells was not affected at 24 h (Fig S2C).
Figure 1. SP-D and rhSP-D recognize HIV-1 gp41, gp120 and gp160. (A) A representative image of a ligand blot analysis (n = 3) using a
ready-to-use HIV-1 antigen PVDF strip, probed with SP-D or rhSP-D (1 mg/ml) in presence of 2 mM CaCl2 and developed using a monoclonal antibody
against human SP-D and a 1:1000 anti-mouse IgG-peroxidase. SP-D and rhSP-D specifically bind to HIV-1 glycoproteins gp41, gp120 and gp 160. (B)
ELISA assay showing the binding of different concentrations of SP-D (solid line) and rhSP-D (dotted line) to immobilized recombinant r-gp120 (2 mg/
mL). SP-D or rhSP-D bind to gp120 in the presence of 5 mM CaCl2, and the interaction is inhibited by 1 mM EDTA. Each data point represents the
mean 6 S.D. (n = 4). {, * shows a statistically significant increase in the binding of SP-D or rhSP-D respectively to HIV-1 gp120 in the presence of
calcium compared to EDTA (p,0.05) (C) A representative histogram of FITC labeled gp120 on HL2/3 cells (n = 3). HIV-1 gp120 expressing HL2/3 cells
were incubated with rhSP-D (2 mg/mL) or no rhSP-D and further probed with a polyclonal FITC-tagged anti-gp120 antibody. In presence of rhSP-D,
significantly lesser FITC signal was detected by flow cytometry (gray tinted histogram) comparing to no rhSP-D (black lined histogram).
doi:10.1371/journal.pone.0102395.g001
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rhSP-D modulates the phosphorylation of Akt and
MAPKs in HIV-1 challenged Jurkat T cells and U937
monocytes
PI3K activation can lead to the phosphorylation and activation
of Akt [22,23]. PI3K/Akt pathway is critical for regulating
secretion of pro-inflammatory cytokines that promote HIV-1
infection [24]. Phosphorylation of Akt was significantly reduced in
the rhSP-D treated T cells and monocytes. Like Akt, phosphor-
ylation of both p38 and Erk1/2 MAPK was significantly decreased
in rhSP-D treated cells, indicating the contribution of rhSP-D
restricted signal transduction in bringing down the cytokine
response to HIV (Fig 6).
Discussion
Here, we show the anti-HIV-1 activity of a recombinant
fragment of human SP-D containing trimeric CRDs (rhSP-D) and
its ability to contain the viral replication in Jurkat T cells, U937
monocytes and activated PBMCs in vitro. We also demonstrate
that rhSP-D, similar to full length human SP-D, recognizes the
envelope glycoprotein gp120 that binds to CD4, initiating an
intracellular signaling cascade that sets up viral infection in target
cells. Importantly, both rhSP-D and SP-D inhibited interaction
between gp120 and CD4 in a dose-responsive manner and
downregulated the spiraling immune activation.
Interaction of rhSP-D with gp120 is a calcium dependent, lectin
activity of the CRD similar to that of SP-D reported previously
[14,15]. It is likely that SP-D (and rhSP-D) interacts with gp41 and
gp160 in a similar manner through its lectin domains. HIV-1
gp120 interacts with CD4 and co-receptors CXCR4 or CCR5
whereas gp41 assists in the fusion of the viral membrane to the cell
membrane [25]. Thus, SP-D may regulate viral binding and fusion
with the target cells. Consistent with this notion, both SP-D and
rhSP-D inhibited the interaction between solid-phase or surface
expressed gp120 and CD4. This is in contrast to a recent paper
that reported that SP-D failed to inhibit the gp120-CD4
interaction in solution phase [15]. The differences in the two
results ([15] and this study) may reflect on the assay systems used.
It is also likely that steric hindrance imposed by rhSP-D bound
gp120 may specifically inhibit interaction with membrane bound
CD4. The steric context may be somewhat different for virion
gp120 binding to soluble CD4 compared to membrane bound
CD4, as shown for Cyanovirin-N, a potent gp120 binding lectin
and an entry inhibitor [26,27]. Inhibition of gp120-CD4
interaction implies that SP-D could affect the gp120 mediated
viral entry. Analysis of the docked complex revealed that the
binding regions of CRD of SP-D and CD4 in gp120 are proximal,
and therefore, it is highly likely that SP-D (CRD) can impair/
inhibit CD4 binding of gp120. Furthermore, the glycans of
Asn234 and Asn276 are implicated in the neutralizing activity of
8ANC195 antibody, which is an anti-gp120 antibody, secreted by
sorted single B cell from a patient with high titers of broadly
neutralizing antibodies that bind to an HIV gp120 core
glycoprotein stabilized in the CD4-bound conformation and
lacking the variable (V loops 1 to 3) (2CC core) [20,28]. Asn234
seems to be relevant for viral infectivity as exposure to an
increasing concentration of Urtica dioica agglutinin (UDA), a
carbohydrate binding agent, results in a selection pressure on
Asn234 to Ile234 and the mutant virus showed reduced infectivity
[29]. Glycosylated Asn276 is also a contact site for the broadly
neutralizing antibody VRC01 [30]. SP-D shared interactions with
the glycans of these residues in the docked complex, further
strengthening its potential as a viral entry inhibitor. The gp120-
CD4 fusion assay using HL2/3 cells corroborated that SP-D and
rhSP-D act as potent cell entry inhibitors to HIV-1.
Binding of gp120 to CD4 on the surface of T cells, DCs, and
macrophages result in the production of cytokines such as IL-6,
IL-10, TNF-a, IFN-a, IFN-c and IL-1b [31]. A recent report has
Figure 2. SP-D and rhSP-D interfere with binding of gp120 to CD4. (A) Docked solution displaying SP-D timer docked with glycosylated
model of HIV-1 glycoprotein gp120. (i) SP-D trimer (light green, dark green and orange cartoon) interacting with HIV-1 gp120 (grey cartoon) (ii) SP-D
trimer (green) bound proximal to the CD4 binding region of gp120 (PDB ID: 1GC1). The CD4 (red cartoon) binding regions C2 (D loop), C4 and C5 of
gp120 are depicted as light red, purple and cyan surfaces, respectively. Asn234 is depicted in blue and Asn276, a part of C2 domain is depicted in
light red. (iii) Enlarged image of site where SP-D and CD4 interact on gp120 (B) To assess whether SP-D or rhSP-D interfered with gp120 and CD4
binding, PBMCs were incubated together with r-gp120 (2 mg/mL) and SP-D or rhSP-D (1 and 2 mg/ml) in 5 mM CaCl2. The interaction was probed
using a polyclonal FITC-tagged anti-gp120 antibody. Cells were acquired on a flow cytometer. (i) Lymphocyte population was gated. Differences in
the FITC positive gated lymphocytes were calculated in terms of % inhibition. (ii) Mean fluorescence intensity was converted to % FITC positive cells.
rhSP-D (at 1 mg 74.3260.5%, at 2 mg 48.3263.2%) showed a significant reduction in FITC positive cells as compared to untreated control. (iii) rhSP-D
(at 10 mg–28.7362.8%) showed a significant reduction in FITC positive cells as compared to untreated control. The data is a representative image of 4
independent experiments. A similar experiment was conducted using SP-D (data not shown) (C) Fusion experiment where HL2/3 cells that express
gp120 were incubated with indicated concentrations rhSP-D or SP-D in presence of 5 mM CaCl2. These cells were fused with TZM-bl cells that express
CD4. The interaction of gp120 and CD4 is directly proportional to the blue color foci observed under a light microscope in TZM-bl cells. Each data
point represents the mean6 S.D. (n = 3). Presence of SP-D and rhSP-D significantly decreased gp120 and CD4 binding and further b-gal positive TZM-
bl cells.
doi:10.1371/journal.pone.0102395.g002
Figure 3. Broad spectrum anti-HIV activity of rhSP-D. (A) TZM-bl
indicator assay to assess anti-HIV activity using rhSP-D and full-length
SP-D (20 mg/ml). Each bar represents the mean 6 SEM (n= 4). ** shows
statistical significance in the reduction of b-gal positive cells compared
to the untreated control (**p,0.01). B) TZM-bl indicator assay to assess
anti-HIV activity of rhSP-D with different HIV-1 isolates and with various
indicated concentrations. Each bar represents the mean 6 SEM. (n = 4).
rhSP-D showed a significant (p,0.05) reduction of b-gal positive cells as
compared to the untreated control C) Post-coital efficacy of rhSP-D
against HIV-1 using TZM-bl indicator assay. Diluted CVL was pre-
incubated with indicated concentrations of rhSP-D for 1 h. 100 TCID50
of HIV-1 USNG31 were pre-incubated with undiluted SP-D for 1 h. These
were mixed, incubated, and later added to TZM-bl cells. Each bar
represents the mean6 SEM. (n = 4). rhSP-D showed significant (p,0.05)
reduction of b-gal positive cells as compared to the untreated control.
doi:10.1371/journal.pone.0102395.g003
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shown that individuals with detectable gp120 had higher levels of
plasma IL-6, IL-10, and TNF-a [32]. A number of in vitro and in
vivo studies have correlated the elevated levels of pro-inflamma-
tory cytokine/chemokine during acute HIV infection with
increased viral load and enhanced pathogenesis [1,3,33–40]. We
also observed a significant increase of pro-inflammatory cytokines
when HIV-1 was challenged to PBMCs, U937 monocytes and
Jurkat T cells in vitro. Since rhSP-D interferes with gp120/CD4
interaction, it can block the gp120-CD4 triggered rise of pro-
inflammatory cytokines in HIV challenged cells. In the case of
U937 cells, rhSP-D significantly reduced levels of IL-2, IL-6, IFN-
, VEGF and MCP-1. Similarly rhSP-D treatment lowered
expression of IL-2, TNF-a, IFN- , IL-1a and VEGF in HIV
infected Jurkat cells. Activated PBMCs showed a significant
decrease in cytokines including, IL-2, IFN- , TNF-a, IL-1a, IL-1b
and VEGF. Since these cytokines are involved in non-specific
immune activation, infiltration of cells and viral replication, SP-D
may be playing a vital role in modulating the acute phase immune
response to HIV challenge. Such a controlled cytokine milieu may
aid in reducing the susceptibility of target cells to infection and
facilitate a protective anti-HIV response. Similarly, SP-D has been
shown to be protective and anti-inflammatory in mouse models of
other viral infections like Influenza A Virus and Respiratory
Syncytial Virus [41,42].
Binding of HIV-1 to CD4 activates the MEK/Erk kinase
pathway, stimulates the expression of nuclear factors, and results
in the expression of inflammatory genes [43]. Signaling through
p38 and Erk pathways could be a common link between HIV
replication and immune response [44]. HIV infection also
activates cellular PI3/Akt pathway that promote viral replication.
Table 1. Summary of the calculated IC50 values for rhSP-D-mediated inhibition of HIV-1 with envelopes from subtypes B and C
and different cell types.
Cell type Assay Viral Strain Subtype Tropism IC50 (mg/ml)
TZM-bl Reporter Assay HIV-1 LAI(BRU) B X4 10.8760.5
TZM-bl Reporter Assay HIV-1 93IN905 C R5 6.7260.63
TZM-bl Reporter Assay HIV-1 98IN017 C X4 8.9560.51
TZM-bl Reporter Assay HIV-1 96USNG31 C R5X4R3 7.2660.52
PBMCs p24 Antigen ELISA HIV-1 96USNG31 C R5X4R3 9.6762.6
Jurkat T cells p24 Antigen ELISA HIV-1 96USNG31 C R5X4R3 13.6763.37
U937 monocytes p24 Antigen ELISA HIV-1 96USNG31 C R5X4R3 10.2261.37
doi:10.1371/journal.pone.0102395.t001
Figure 4. rhSP-D inhibits HIV-1 infection of Jurkat T cells, U937
monocytic cells and activated PBMCs. 100 TCID50 of HIV-1 USNG31
and indicated concentrations of rhSP-D in presence of 5 mM CaCl2 were
incubated for 1 h. The virus-collectin complex was then added to cells
for 4 h and unbound residual virus was removed. Fresh media was
added to the cells and a sample of culture supernatant was taken every
3 days for p24 quantification by ELISA and replaced with new media. On
day 12, viability was assessed by an MTT assay, which indicated no
cellular death (Figure S2B). (A) Dose-dependent inhibition of HIV
infection in Jurkat T cells; (B) Dose-dependent inhibition of HIV
infection in U937 monocytic cells; (C) Dose-dependent inhibition of
HIV-1 infection in PHA-activated PBMCs. Each data point represents the
mean 6 S.D. (n = 3). rhSP-D showed significant (p,0.05) reduction of b-
gal positive cells as compared to untreated control. (D) Day 6 culture
supernatants of Jurkat T cells, U937 monocytic cells and activated
PBMCs were used to determine the concentration for a 50% reduction
in p24 production in each cell type. Each bar represents the mean 6
S.D. (n = 3).
doi:10.1371/journal.pone.0102395.g004
Figure 5. rhSP-D inhibits pro-inflammatory cytokine produc-
tion of HIV-1 challenged Jurkat T cells, U937 monocytic cells
and activated PBMCs. Jurkat T cells, U937 monocytes and activated
PBMCs were treated with indicated concentrations of rhSP-D, 20 min
prior to HIV-1 challenge. 24 h post viral challenge, culture supernatant
were collected and assayed for cytokine levels by a multiplex system.
(A) Dose-dependent % inhibition of rhSP-D-treated HIV-1 challenged
cytokines IL-2, TNF-a, IFN-c, IL-1a, VEGF as compared to HIV alone in
Jurkat T cells. Each bar represents the mean 6 S.D. (n = 3). rhSP-D
showed significant (p,0.05) reduction in the levels of these pro-
inflammatory cytokines. (B) Dose-dependent % inhibition of rhSP-D-
treated HIV-1 challenged cytokines IL-2, IL-6, IFN-c, MCP-1, VEGF as
compared to HIV alone in U937 monocytes. Each bar represents the
mean 6 S.D. (n = 3). rhSP-D showed significant (p,0.05) reduction in
the levels of these pro-inflammatory cytokines. (C) Dose-dependent %
inhibition of rhSP-D treated HIV challenged cytokines IL-2, IFN-c, TNF-a,
IL-1a, IL-1b, VEGF as compared to HIV alone. Each bar represents the
mean 6 S.D. (n = 3). rhSP-D showed significant (p,0.05) reduction in
the levels of these pro-inflammatory cytokines.
doi:10.1371/journal.pone.0102395.g005
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The PI3-kinase effectors Akt and p70 S6 kinase have been shown
to phosphorylate in response to both soluble and virion-associated
R5 and X4 gp120 in primary CD4 T lymphocytes [24]. A rhSP-D
mediated interference between gp120 and CD4 interaction
probably explains a significant reduction in phosphorylation of
Akt, p38 and Erk1/2 in HIV-1 challenged Jurkat and U937 cells.
Thus, in addition to inhibiting the gp120 mediated virion entry
into the target cells, SP-D also dampens activation of signaling
pathways, leading to modulation of pro-inflammatory cytokine
production by target cells. Having used four HIV strains that differ
with respect to subtypes (env) B and C and X4, R5 or dual tropic
strains, we infer that the inhibitory activity of rhSP-D against HIV-
1 is broad, independent of tropism, dose-dependent, and effective
against subtype B and C envelope sequences. This could be, in
part, attributed to presence of well conserved mannosylated
domains of gp120 among various virus subtypes, an advantage
associated with agents targeting HIV glycans [45].
Considering that more than 85% of HIV transmission occurs
due to heterosexual contact and SP-D is present in the vaginal
tract [16], we sought to assess the post-coital efficacy of rhSP-D to
inhibit HIV infectivity. An effective inhibition of HIV-1 infection
in TZM-bl cells was observed in presence of CVL and SP. SP-D
has been reported to be present in the vaginal tract and is localized
on human spermatozoa and seminal plasma of stallion [46,47].
Thus, it was unlikely to be inhibited or inactivated in these fluids.
Our results lend support to the idea that SP-D plays an important
role in curbing the post-coital HIV-1 infection and transmission in
vivo. This raises the possibility that rhSP-D can be effectively used
as a prophylactic intervention strategy at the mucosal level.
In conclusion, the study has enabled us to assign specific roles to
SP-D in host defense against HIV. SP-D appears to play a
protective role by enhancing viral clearance via its recognition of
the glycosylated envelope of HIV-1, inhibiting viral entry by
blocking access of envelope glycoproteins to the cell surface
receptors, and thus, interfering with virus internalization by host
cells as well as with reduced signal transduction, immune cell
activation and pro-inflammatory cytokine production, resulting in
reduced viral loads. As genital mucosal compartment is the usual
portal of entry for HIV and other STI pathogens, the local
production of SP-D is likely to play a role in innate defense
responses against the virus. The study emphasizes the potential of
Figure 6. rhSP-D modulates the phosphorylation of Akt and MAPKs upon HIV-1 challenge. 56105 Jurkat T cells or U937 monocytic cells
were treated with rhSP-D (10 mg/ml) in presence of 5 mM CaCl2 and HIV-1USNG31. After 30 min, cell were harvested, lysed, and SDS-PAGE and
Western blots were performed using pAKT, p-p38 and p-Erk1/2 or b-actin (house-keeping control) antibodies. Representative Western blots (A) and
(C) and bar graphs (B) and (D), generated by densitometric analysis for Jurkat and U937 cells, respectively. Each bar represents the mean 6 S.D.
(n = 3). *, ** shows statistical significant % inhibition cytokine levels of HIV-1 infection by rhSP-D in each cell type as compared to control (*p,0.05,
**p,0.01) represent cumulative data.
doi:10.1371/journal.pone.0102395.g006
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rhSP-D for translational applications in the HIV related
healthcare.
Materials and Methods
Ethics Statement
Written informed consent was obtained from each study
participant and recommended guidelines were followed during
sample collection. The study was approved by the Institutional
Ethics Committee for Clinical Studies, National Institute for
Research in Reproductive Health (ICMR); (Project 148/2008),
and recommended guidelines were followed during collection of
blood, vaginal lavage and seminal plasma from the study
participants. For purification of SP-D from the amniotic fluid
collected at term, the study was approved by the Institutional
Ethics Committee for Clinical Studies, National Institute for
Research in Reproductive Health (ICMR); (Project 153/2009),
and Ethics Committee of KEM Hospital and Seth GS Medical
College; Project (EC/GOVT-6/2009).
Viral strains
Four HIV-1 strains namely LAI (X4 tropic), 93IN905 (R5
tropic, env. subtype C), 98IN017 (utilizes X4, env. subtype C),
96USNG31 (utilizes R5X4R3, env. subtype C) were obtained
from NIH-AIDS Research and Reference Reagent Program,
USA.
PBMCs and Cell lines
TZM-bl and HL2/3 cell lines were obtained from NIH-AIDS
Research and Reference Reagent Program, USA whereas, Jurkat
T and U937 monocytic cell lines were procured from Cell
Repository Facility, National Center for Cell Sciences, Pune,
India. TZM-bl cells were cultured in DMEM/F12 medium
(Sigma) containing 10% FBS (Gibco) and 1% Pen-Strep (Gibco).
HL2/3 cells were cultured in complete DMEM/F12 containing
G418 (Geneticin from Gibco) at a concentration of 50 mg/ml.
Jurkat T and U937 monocytic cell lines were cultured in RPMI-
1640 medium (Sigma). Cells were sub-cultured every 2-3 days and
those at the log phase of growth were used for the experiments.
Peripheral Blood Mononuclear Cells (PBMCs) pooled from
different study participants were procured from Himedia Labo-
ratories. Cells were cultured in RPMI 1640 medium containing
10% FBS (Gibco) in the presence of phytohemaglutinin (PHA)
(Gibco). PHA was washed off after 24 h and cells were cultured
further in complete RPMI medium.
Collection of Cervico-vaginal lavage (CVL)
After obtaining written informed consent, proliferative phase
CVL from normal cycling females (25–32 years; n = 5) was
collected by placing a #2 Pederson speculum in the vagina and
instilling 3 ml 0.9% sterile saline into the speculum. A 5 ml syringe
was used to rinse vaginal walls once, and the lavage fluid was then
withdrawn from the speculum. Lavage was passed through a
syringe filter (0.22 micron) and was frozen at 280uC immediately.
Collection of Seminal plasma (SP)
Written consent was obtained from healthy males, age (27–35;
n = 5) and semen sample was collected. Sperms were pelleted and
seminal plasma was recovered and stored at 280uC.
hSP-D preparation
Native human SP-D (hSP-D) was purified from the human
amniotic fluid obtained from pregnant women at term undergoing
caesarean section, using procedures described previously [48,49].
The protein preparation was confirmed to be pure by SDS-PAGE
and western blot analysis.
Recombinant form of SP-D preparation
The rhSP-D was expressed in E. coli, purified and characterized
as described previously [50]. The rhSP-D preparation was
examined for endotoxin levels using the QCL-1000 Limulus
amebocyte lysate system (BioWhittaker Inc., USA). The assay was
linear over a range of 0.1–1.0 EU/ml (10 EU = 1 ng of endotoxin)
and the amount of endotoxin present in the preparations was
estimated to be 4 pg/mg of rhSP-D.
Study on interactions of SP-D and gp120
(A) Ligand Blot analysis. HIV antigen PVDF strips (MP
Diagnostics) were probed with 1 mg/ml of SP-D or rhSP-D in Tris
buffer saline (TBS, 0.01 M, pH 7.4) containing 5 mM CaCl2 at
room temperature for 1 h. The strip was washed three times with
TBS containing 0.05% Tween-20 followed by incubation with
1:100 diluted monoclonal antibody against human SP-D (Abcam).
After washing, the strip was incubated with 1:1000 anti-mouse
IgG-peroxidase (Dako) and was developed using ECL detection
system.
(B) ELISA to examine gp120-SP-D interaction. 2 mg r-
gp120 (Xpress Bio) was immobilized on 96-well Maxisorp plates
(Nunc) in 0.1 M sodium bicarbonate buffer (pH 9.6) overnight at
4uC. The wells were washed with PBS and 0.05% (v/v) Tween 20
(PBST) and blocked in 3% (v/v) BSA for 1 h at 37uC. After
washing away excess BSA with PBST, the wells were incubated
with increasing concentrations of SP-D or rhSP-D (0–10 mg/ml) in
Tris buffer saline calcium (TBSC; 20 mM Tris-HCl, 150 mM
NaCl, 5 mM CaCl2, pH 7.4), or Tris-saline EDTA (TBSE;
20 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, pH 7.4). The
gp120-SP-D/rhSP-D complexes were detected using a biotiny-
lated polyclonal antibody for SP-D (Abcam) and HRP-Streptavi-
din (Santa Cruz Antibodies Inc.) and H2O2-TMB (Sigma). The
absorbance (450 nm) of individual wells was measured by a
spectrophotometer (Beckman Coulter).
(C) Binding of SP-D to cell surface expressed gp120 on
HL2/3 cells. HeLa-derived HL2/3 cells, which express HIV-
1HXB2 Env on the cell surface in addition to Tat, Gag, Rev, and
Nef proteins in the cytoplasm [51], were treated with or without
SP-D or rhSP-D (2 mg/ml) on ice for 1 h. Cells were then labeled
with anti-gp120/FITC antibody. Differences in FITC positive
cells in control versus treated were analyzed by FACS (BD FACS
Aria III).
(D) Protein Docking. The structures of human lung
surfactant protein D (PDB ID: 1PW9) [52] in the trimeric form
and HIV-1 envelope glycoprotein gp120 complexed with two-
domain fragment of human CD4 receptor (PDB ID: 1GC1)
modeled with glycans [53] were docked using PatchDock server
with default parameters [54]. The shortlisted poses were refined
using FireDock [55].
Effect of SP-D on interaction between gp120 with CD4
(A) Competitive inhibition assay for soluble gp120
binding to CD4 on lymphocytes. To assess whether SP-D
or rhSP-D intervention inhibited the interaction between gp120
and CD4, PBMCs were incubated with or without SP-D or rhSP-
D (1, 2 mg/ml) and gp120 (2 mg) on ice for 45 min. Cells were then
probed with anti-gp120/FITC antibody (Fitzgerald, USA). Lym-
phocyte population was gated and FITC positive cells were
analyzed immediately by FACS.
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(B) Assay for cell surface expressed gp120 dependent
entry inhibition. HL2/3 cells were co-cultured with TZM-bl
cells that express CD4 and CXCR4/CCR5, respectively, at a 1:1
cell density ratio (26104 cell/well each) for 18 h with or without
SP-D or rhSP-D (0–20 mg/ml) in order to examine whether SP-D
or rhSP-D interferes with the binding of HIV-1 Env with cell
surface receptor/co-receptor. Upon fusion of TZM-bl and HL2/3
cells, Tat protein from HL2/3 cells activates b-galactosidase
indicator gene expression in TZM-bl cells. The fused cells, seen as
blue foci, were counted under a light microscope. The number of
blue colored foci is directly proportional to the fused cells, and
thus, gp120-CD4 interaction can be assessed.
Anti-HIV assays
(A) Indicator Assay. HIV-1 infection was quantified using
TZM-bl cells, which express luciferase as well as b-galactosidase
genes under the control of HIV-1 LTR promoter [56]. TZM-bl
cells (66103) were grown in a 96-well tissue culture plate for 24 h.
In separate tubes, 100 TCID50 units of HIV-1 (strains: HIV-
1LAI, HIV-1 IN93/905, HIV-1 98/IN/017 and HIV-1
96USNG31) were pretreated with indicated concentrations of
rhSP-D in presence 5 mM CaCl2 for 1 h at 37uC. The rhSP-D
opsonized virus was allowed to infect TZM-bl cells. After 4 h,
excess virus was washed with 50 mM PBS, fresh medium was
added, and then cells were incubated for an additional 48 h. Next,
cells were washed twice with PBS, fixed in 1% glutaraldehyde for
10 min at room temperature, followed by treatment with X-gal
staining solution (10 ml PBS with 1 mg/ml X-gal dissolved in
DMF, 100 mM potassium ferricyanide, 100 mM potassium
ferrocyanide and 1 mM MgCl2) for 24 h at 37uC. The blue
stained (b-gal expressing) foci were counted under the microscope.
In a parallel experiment, viability of cells was determined by MTT
assay after 48 h as described earlier [57].
(B) Anti-HIV activity in presence of CVL and
SP. Majority of the HIV transmission occurs due to heterosexual
contact. Thus, it was important to re-confirm the anti-HIV activity
of rhSP-D in presence of vaginal lavage and seminal plasma. To
evaluate the post-coital efficacy of anti-HIV activity of rhSP-D,
100 TCID50 of HIV-1 96USNG31 (R5X4R3 tropic) was mixed
with 50 ml of undiluted seminal plasma and incubated for 1 h. The
rhSP-D at indicated concentrations in presence of 5 mM CaCl2
was mixed with 100 ml diluted CVL (pH 5) and incubated for 1 h.
Later, the virus in the seminal plasma and the rhSP-D in the
lavage were mixed and incubated for 2 h [58]. The experimental
conditions were created to mimic the vaginal milieu during sexual
contact. Further, the pretreated virus with CVL and SP was added
to TZM-bl cells and the assay was carried out as described above.
(C) Quantitation of p24 levels in culture supernatants. A
day prior to viral challenge, 56104 of Jurkat, U937, or PHA
activated PBMCs were incubated in RPMI 1640 medium
containing 10% FBS. Different concentrations of rhSP-D in
presence of 5 mM CaCl2 were pre-incubated with 100 TCID50 of
HIV-1 96USNG31 for 1 h before being exposed to target cells.
After 4 h, residual virus was removed, cells were washed and fresh
medium was added. On day 3, 6, 9 and 12, 100 ml supernatant
was collected and replaced with fresh media. The samples were
stored at 280uC until viral replication was determined by the
HIV-1 p24 Antigen Capture Assay ELISA (Xpress Bio). On day
12, MTT assay was performed to assess cellular viability. The p24
values of day 6 supernatant were used to calculate the IC50
concentration of rhSP-D.
Kinase activity and cytokine analysis
U937 or Jurkat cells (56105 cells) were seeded in a 24-well plate
overnight. Cells were then treated with rhSP-D in presence of
5 mM CaCl2 at the concentration of 10 and 40 mg/ml for 20 min
prior to HIV-1 challenge. After HIV challenge, cells were
harvested after 30 min for analyzing phosphorylation of Erk1/2,
p38 and AKT (Cell Signaling). Subsequently, 24 h culture
supernatants were collected for cytokine analysis using Cytokine
Array 1 kit for IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IFN- ,
TNF-a, MCP-1, VEGF, EGF on Evidence Investigator, a
multiplex system that uses Biochip Array Technology (Randox
Laboratories).
Statistical Analysis
Data are expressed as Mean 6 SEM. Dose response
relationships were evaluated using one-way ANOVA, and post-
hoc comparisons between individual treatments were made using
Tukey’s test. Instances involving only two comparisons were
evaluated by paired Student’s t-tests. A value of p,0.05 was
considered statistically significant.
Supporting Information
Figure S1 Selected Docked Poses. Patchdock poses (i), (ii)
and (iii) exhibiting the CRD of SP-D trimer (light green, dark
green and orange cartoon) interacting via glycans modeled on
glycoprotein gp120 (grey cartoon) were further refined by
FireDock. Best Pose (ii) was further analyzed in the study.
(TIF)
Figure S2 MTT assay to evaluate viability of rhSP-D
treated uninfected and infected cells. (A) Viability of TZM-
bl cells treated with rhSP-D at 48 h post-infection. Each bar
represents the mean 6 S.D. (n = 4). (B) Viability of Jurkat T cells,
U937 monocytes and activated PBMCs treated with rhSP-D on
day 12 of infection. Each bar represents the mean 6 S.D. (n = 3).
(C) Viability of Jurkat T cells, U937 monocytes and activated
PBMCs treated with rhSP-D at 24 h post HIV-1 infection. Each
bar represents the mean6 S.D. (n = 3). These different time points
with different cells are in coherence with the anti-HIV and
differential cytokine expression assays carried out in the present
study. Data suggest that viability of cells was not affected by rhSP-
D during experiments for anti-HIV activity and differential
cytokine expression.
(TIF)
Table S1 Ranking and energy for solutions refined
using FireDock.
(DOCX)
Table S2 Levels of cytokines (pg/ml) in culture super-
natants of Jurkat T cells on treatment with indicated
concentration of rhSP-D, HIV-1 and HIV-1 and rhSP-D.
(DOCX)
Table S3 Levels of cytokines (pg/ml) in culture super-
natants of U937 cells on treatment with indicated
concentration of rhSP-D, HIV-1 and HIV-1 and rhSP-D.
(DOCX)
Table S4 Levels of cytokines (pg/ml) in culture super-
natants of PBMCs on treatment with indicated concen-
tration of rhSP-D, HIV-1 and HIV-1 and rhSP-D.
(DOCX)
SP-D Inhibits HIV-1 Entry into Target Cells
PLOS ONE | www.plosone.org 9 July 2014 | Volume 9 | Issue 7 | e102395
Acknowledgments
We thank Dr. S. D. Kholkute, Director, National Institute for Research in
Reproductive Health, Mumbai, for his support. We are extremely grateful
to Dr. Peter Kwong and Marie Pancerea, Structural Biology Section,
NIAIDS, NIH for providing PDB co-ordinates of HIV-1 gp120 modeled
with glycans. TZM-bl and HL2/3 cell lines were a gift from Dr. Satish
Gupta, National Institute of Immunology, New Delhi, India. The following
reagents were obtained through the NIH AIDS Reagent Program, Division
of AIDS, NIAID, NIH: HIV-1LAI from Dr. Jean-Marie Bechet and Dr.
Luc Montagnier, HIV-1 93IN905 from Dr. Robert Bollinger, HIV-1
98IN017 from The UNAIDS Network for HIV Isolation and Character-
ization, HIV-1 96USNG31 from Drs. D. Ellenberger, P. Sullivan, and
R.B. Lal. We are grateful to Dr. Ritwik Dahake and Dr. Abhay
Chowdhary, Haffkine Institute for Training, Research and Testing,
Mumbai for providing Multiplex Cytokine Facility. UK acknowledges
Brunel University Infrastructure Funding towards a Level 3 containment
laboratory.
Author Contributions
Conceived and designed the experiments: HP UK TM. Performed the
experiments: HP SG AS TM. Analyzed the data: HP AS TM SIT.
Contributed reagents/materials/analysis tools: AKY ASQ HW AP RG
VK MAA UK. Contributed to the writing of the manuscript: HP AS SIT
UK TM.
References
1. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, et al. (2009) Induction of
a striking systemic cytokine cascade prior to peak viremia in acute human
immunodeficiency virus type 1 infection, in contrast to more modest and delayed
responses in acute hepatitis B and C virus infections. J Virol. 83(8):3719–3733.
doi: 10.1128/JVI.01844-08.
2. Herbein G, Gras G, Khan KA, Abbas W (2010) Macrophage signaling in HIV-1
infection. Retrovirology. 7: 34. doi: 10.1186/1742-4690-7-34.
3. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS (1998) Induction of HIV-1
replication in latently infected CD4+ T cells using a combination of cytokines. J
Exp Med. 6;188(1):83–91.
4. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF (2010) The
immune response during acute HIV-1 infection: clues for vaccine development.
Nat. Rev. Immunol. 10(1):11–23. doi: 10.1038/nri2674.
5. Nayak A, Dodagatta-Marri E, Tsolaki AG, Kishore U (2012) An Insight into the
Diverse Roles of Surfactant Proteins, SP-A and SP-D in Innate and Adaptive
Immunity. Front Immunol. 7; 3: 131. doi: 10.3389/fimmu.2012.00131.
6. Kishore U, Greenhough TJ, Waters P, Shrive AK, Ghai R, et al. (2006)
Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol.
Immunol. 43(9):1293–1315.
7. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, et al. (2003) By
binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function
surveillance molecules to suppress or enhance inflammation. Cell 115(1):13–23.
8. Jakel A, Qaseem AS, Kishore U, Sim RB (2013) Ligands and receptors of lung
surfactant proteins SP-A and SP-D. Front Biosci 18: 1129–1140.
9. Yamazoe M, Nishitani C, Takahashi M, Katoh T, Ariki S, et al. (2008)
Pulmonary surfactant protein D inhibits lipopolysaccharide (LPS)-induced
inflammatory cell responses by altering LPS binding to its receptors. J Biol
Chem. 283(51):35878–35888. doi: 10.1074/jbc.M807268200.
10. Borron PJ, Crouch EC, Lewis JF, Wright JR, Possmayer F, et al. (1998)
Recombinant rat surfactant-associated protein D inhibits human T lymphocyte
proliferation and IL-2 production. J Immunol. 161(9):4599–4603.
11. Borron PJ, Mostaghel EA, Doyle C, Walsh ES, McHeyzer-Williams MG, et al.
(2002) Pulmonary surfactant proteins A and D directly suppress CD3+/CD4+
cell function: evidence for two shared mechanisms. J Immunol. 169(10):5844–
5850.
12. Lin KW, Jen KY, Suarez CJ, Crouch EC, Perkins DL, et al. (2010) Surfactant
protein D-mediated decrease of allergen-induced inflammation is dependent
upon CTLA4. J Immunol. 184(11):6343–6349. doi: 10.4049/jimmu-
nol.0901947.
13. Clark H, Reid KB (2003) The potential of recombinant surfactant protein D
therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis,
and emphysema. Arch Dis Child. 88(11): 981–984. doi: 10.1136/adc.88.11.981
14. Meschi J, Crouch EC, Skolnik P, Yahya K, Holmskov U, et al. (2005) Surfactant
protein D binds to human immunodeficiency virus (HIV) envelope protein
gp120 and inhibits HIV replication. J Gen Virol. 86: 3097–3107.
15. Madsen J, Gaiha GD, Palaniyar N, Dong T, Mitchell DA, et al. (2013)
Surfactant Protein D modulates HIV infection of both T-cells and dendritic
cells. PLoS One. 8(3):e59047. doi: 10.1371/journal.pone.0059047.
16. Leth-Larsen R, Floridon C, Nielsen O, Holmskov U (2004) Surfactant protein D
in the female genital tract. Mol Hum Reprod 10: 149–154. doi: 10.1093/
molehr/gah022.
17. Jambo KC, French N, Zijlstra E, Gordon SB (2009) AIDS patients have
increased surfactant protein D but normal mannose binding lectin levels in lung
fluid. Respir Res 13;8: 42.
18. Kunisaki KM, Quick H, Baker JV (2011). HIV antiretroviral therapy reduces
circulating surfactant protein-D levels. HIV Med. 12(9):580–581. doi: 10.1111/
j.1468-1293.2011.00920.x.
19. Li Y, O’Dell S, Walker LM, Wu X, Guenaga J, et al. (2011) Mechanism of
neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
J. Virol. 85(17):8954–8967. doi: 10.1128/JVI.00754-11.
20. West AP Jr, Scharf L, Horwitz J, Klein F, Nussenzweig MC, et al. (2013)
Computational analysis of anti-HIV-1 antibody neutralization panel data to
identify potential functional epitope residues. Proc Natl Acad Sci U S A.
110(26):10598–10603. doi: 10.1073/pnas.1309215110.
21. Clevestig P, Pramanik L, Leitner T, Ehrnst A (2006) CCR5 use by human
immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-
linked glycosylation site. J Gen Virol. 87(Pt 3):607–612.
22. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, et al. (1997) Dual
role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein
kinase B. Science 277: 567–570.
23. Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, et al. (1998) Akt
activation by growth factors is a multiple-step process: the role of the PH
domain. Oncogene 17: 313–325.
24. Franc¸ois F, Klotman ME (2003) Phosphatidylinositol 3-kinase regulates human
immunodeficiency virus type 1 replication following viral entry in primary CD4+
T lymphocytes and macrophages. J Virol. 77(4):2539–2549.
25. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, et al. (2003) The HIV
Env-mediated fusion reaction. Biochim Biophys Acta. 1614(1):36–50.
26. Parren PW, Mondor I, Naniche D, Ditzel HJ Klasse PJ, et al. (1998)
Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is
determined primarily by occupancy of sites on the virion irrespective of epitope
specificity. J. Virol. 72: 3512–3519.
27. Esser MT, Mori T, Mondor I, Sattentau QJ, Dey B, et al. (1999) Cyanovirin-N
binds to gp120 to interfere with CD4-dependent human immunodeficiency virus
type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding
site on gp120 or soluble CD4-induced conformational changes in gp120. J Virol.
73(5):4360–4371.
28. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, et al. (2011) Sequence
and structural convergence of broad and potent HIV antibodies that mimic CD4
binding. Science 333(6049):1633–1637.
29. Balzarini J, Van Laethem K, Hatse S, Froeyen M, Peumans W, et al. (2005)
Carbohydrate-binding agents cause deletions of highly conserved glycosylation
sites in HIV GP120: a new therapeutic concept to hit the achilles heel of HIV. J
Biol Chem. 280(49):41005–41014.
30. Li Y, O’Dell S, Walker LM, Wu X, Guenaga J, et al. (2011) Mechanism of
neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
J Virol. Sep;85(17):8954–67. doi: 10.1128/JVI.00754-11.
31. Chirmule N, Pahwa S (1996) Envelope glycoproteins of human immunodefi-
ciency virus type 1: Profound influences on immune functions. Microbiol Rev.
60(2):386–406.
32. Rychert J, Strick D, Bazner S, Robinson J, Rosenberg E (2010) Detection of
HIV gp120 in plasma during early HIV infection is associated with increased
pro-inflammatory and immunoregulatory cytokines. AIDS Res Hum Retrovi-
ruses. 26(10):1139–1145. doi: 10.1089/aid.2009.0290.
33. Longo N, Zabay JM, Sempere JM, Navarro J, Ferna´ndez-Cruz E (1993) Altered
production of PGE2, IL-1 beta and TNF-alpha by peripheral blood monocytes
from HIV-positive individuals at early stages of HIV infection. J Acquir Immune
Defic Syndr. 6(9):1017–1023.
34. Biswas P, Poli G, Orenstein JM, Fauci AS (1994) Cytokine-mediated induction
of human immunodeficiency virus (HIV) expression and cell death in chronically
infected U1 cells: do tumor necrosis factor alpha and gamma interferon
selectively kill HIV-infected cells? J Virol. 68(4):2598–604.
35. Zaitseva M, Lee S, Lapham C, Taffs R, King L, et al. (2000) Interferon gamma
and interleukin 6 modulate the susceptibility of macrophages to human
immunodeficiency virus type 1 infection. Blood 96 (9):3109–3117.
36. Poli G, Kinter AL, Fauci AS (1994) Interleukin 1 induces expression of the
human immunodeficiency virus alone and in synergy with interleukin 6 in
chronically infected U1 cells: inhibition of inductive effects by the interleukin 1
receptor antagonist. Proc Natl Acad Sci U S A 91(1):108–112.
37. Graziosi C, Gantt KR, Vaccarezza M, Demarest JF, Daucher M, et al. (1996)
Kinetics of cytokine expression during primary human immunodeficiency virus
type 1 infection. Proc Natl Acad Sci U S A 93(9):4386–4391.
38. Mengozzi M, De Filippi C, Transidico P, Biswas P, Cota M, et al. (1999) Human
immunodeficiency virus replication induces monocyte chemotactic protein-1 in
human macrophages and U937 promonocytic cells. Blood 93(6):1851–1857.
39. Bahbouhi B, Landay A, Al-Harthi L (2004) Dynamics of cytokine expression in
HIV productively infected primary CD4+ T cells. Blood 103(12):4581–4587.
40. Ascherl G, Hohenadl C, Schatz O, Shumay E, Bogner J, et al. (1999) Infection
with human immunodeficiency virus-1 increases expression of vascular
SP-D Inhibits HIV-1 Entry into Target Cells
PLOS ONE | www.plosone.org 10 July 2014 | Volume 9 | Issue 7 | e102395
endothelial cell growth factor in T cells: implications for acquired immunode-
ficiency syndrome-associated vasculopathy. Blood. 93(12):4232–4241.
41. LeVine AM, Whitsett JA, Hartshorn KL, Crouch EC, Korfhagen TR (2001)
Surfactant Protein D Enhances Clearance of Influenza A Virus from the Lung
In Vivo. J Immunol 167: 5868–5873.
42. LeVine AM, Elliott J, Whitsett JA, Srikiatkhachorn A, Crouch E, et al. (2004)
Surfactant protein-D enhances phagocytosis and pulmonary clearance of
respiratory syncytial virus. Am J Respir Cell Mol Biol. 31(2):193–199.
43. Popik W, Hesselger JE, Pitha PM (1998) Binding of human immunodeficiency
virus type 1 to CD4 and CXCR4 receptors differentially regulates the expression
of inflammatory genes and activates the MEK/ERK signaling pathway. J. Virol.
72: 6404–6413.
44. Furler RL, Uittenbogaart CH (2010) Signaling through the P38 and ERK
pathways: a common link between HIV replication and the immune response.
Immunol Res. 2010 48(1–3):99–109. doi: 10.1007/s12026-010-8170-1.
45. Balzarini J (2007) Carbohydrate-binding agents: a potential future cornerstone
for the chemotherapy of enveloped viruses? Antivir Chem Chemother. 18(1):1–
11.
46. Kankavi O, Ata A, Celik-Ozenci C, Sati L, Ciftcioglu MA, et al. (2008) Presence
and subcellular localizations of surfactant proteins A and D in human
spermatozoa. Fertil Steril. 90(5):1904–1909. doi: 10.1016/j.fertnstert.2007.09.
064.
47. Kankavi O, Ata A, Akif Ciftcioglu M (2006) Surfactant protein A and D in the
reproductive tract of stallion. Theriogenology. 66(5):1057–1064.
48. Strong P, Kishore U, Morgan C, Lopez Bernal A, Singh M, et al. (1998) A novel
method of purifying lung surfactant proteins A and D from the lung lavage of
alveolar proteinosis patients and from pooled amniotic fluid. J Immunol
Methods. 220(1–2):139–149.
49. Dodagatta-Marri E, Qaseem AS, Karbani N, Tsolaki AG, Waters P, et al. (2014)
Purification of surfactant protein D (SP-D) from pooled amniotic fluid and
bronchoalveolar lavage. Methods Mol Biol. 1100: 273–290. doi: 10.1007/978-1-
62703-724-2_22.
50. Mahajan L, Madan T, Kamal N, Singh VK, Sim RB, et al. (2008) Recombinant
surfactant protein-D selectively increases apoptosis in eosinophils of allergic
asthmatics and enhances uptake of apoptotic eosinophils by macrophages. Int
Immunol. 2008 20(8):993–1007. doi: 10.1093/intimm/dxn058
51. Ciminale V, Felber BK, Campbell M, Pavlakis GN (1990) A bioassay for HIV-1
based on Env-CD4 interaction. AIDS Res. Hum.Retrovir. 6: 1281–1287.
52. Shrive AK, Tharia HA, Strong P, Kishore U, Burns I, et al. (2003) High-
resolution structural insights into ligand binding and immune cell recognition by
human lung surfactant protein D. J Mol Biol. 331(2):509–523.
53. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, et al. (2010) Structure of
HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture
and basis of conformational mobility. Proc Natl Acad Sci U S A. 107(3):1166–
1171. doi: 10.1073/pnas.0911004107.
54. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ (2005) PatchDock
and SymmDock: servers for rigid and symmetric docking. Nucl. Acids. Res.
33:W363–367.
55. Andrusier N, Nussinov R, Wolfson HJ (2007) FireDock: Fast Interaction
Refinement in Molecular Docking. Proteins 69(1):139–159.
56. Swanson MD, Winter HC, Goldstein IJ, Markovitz DM (2010) A lectin isolated
from bananas is a potent inhibitor of HIV replication. J Biol Chem.
285(12):8646–8655. doi: 10.1074/jbc.M109.034926.
57. Mahajan L, Pandit H, Madan T, Gautam P, Yadav AK, et al. (2013) Human
surfactant protein D alters oxidative stress and HMGA1 expression to induce
p53 apoptotic pathway in eosinophil leukemic cell line. PLoS One. 8(12):e85046.
doi: 10.1371/journal.pone.0085046.
58. Keller MJ, Mesquita PM, Torres NM, Cho S, Shust G, et al. (2010) Postcoital
bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for
future microbicide clinical trials. PLoS One. 5(1):e8781. doi: 10.1371/journal.
pone.0008781.
SP-D Inhibits HIV-1 Entry into Target Cells
PLOS ONE | www.plosone.org 11 July 2014 | Volume 9 | Issue 7 | e102395
